Related Experiment Videos
Metrifonate treatment of AD: influence of APOE genotype
M R Farlow1, P A Cyrus, A Nadel
1Department of Neurology, Indiana University School of Medicine, Indianapolis 46202-5111, USA.
Objective:
To investigate whether an interaction exists between APOE genotype and the response of AD patients to metrifonate treatment and whether APOE genotype independently affects the rate of AD progression.
Background:
Metrifonate is a new acetylcholinesterase inhibitor for the treatment of AD symptoms.
Methods:
Data were pooled from four prospective, randomized, double-blind, placebo-controlled clinical trials and analyzed retrospectively. A total of 959 patients who received once-daily placebo (n = 374) or metrifonate (30 to 60 mg based on weight or a 50-mg fixed dose, n = 585) for up to 26 weeks agreed to APOE genotyping.
Results:
Metrifonate clearly improved the cognitive performance of the AD patients when compared with placebo (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog], p = 0.0001). The interaction of APOE genotype and the metrifonate effect on cognitive performance were not significant (p = 0.25). Metrifonate also clearly improved the global function of the AD patients when compared with placebo (Clinician's Interview-Based Impression of Change with Caregiver Input [CIBIC-Plus], p = 0.0001). The interaction of APOE genotype with the metrifonate effect on global function also was not significant (p = 0.70). No significant three-way interactions were observed among APOE genotype, gender, and response to metrifonate treatment (ADAS-Cog, p = 0.68; CIBIC-Plus, p = 0.26). APOE genotype did not influence disease progression as evaluated by either cognitive performance (ADAS-Cog, p = 0.93) or global function (CIBIC-Plus, p = 0.64).
Conclusions:
The findings from these studies of up to 26 weeks' duration do not clearly support an interaction between APOE genotype and metrifonate treatment effects. They suggest that APOE genotypes do not necessarily predict an AD patient's response to metrifonate treatment and that APOE genotype may not influence the rate of disease progression for patients with mild to moderate AD.
Insights
APOE genotype does not predict Alzheimer's disease (AD) patient response to metrifonate treatment. This study found no significant interaction between APOE genotype and metrifonate's effect on cognitive or global function in AD patients.
Area of Science:
- Neuroscience
- Pharmacogenomics
- Alzheimer's Disease Research
Background:
- Metrifonate is an acetylcholinesterase inhibitor investigated for Alzheimer's Disease (AD) symptom management.
- The apolipoprotein E (APOE) genotype is a known risk factor for AD, prompting investigation into its role in treatment response.
Purpose of the Study:
- To determine if APOE genotype influences patient response to metrifonate treatment for AD.
- To assess whether APOE genotype independently affects the progression rate of Alzheimer's Disease.
Main Methods:
- Pooled data from 959 patients across four randomized, double-blind, placebo-controlled trials of metrifonate.
- Retrospective analysis of metrifonate treatment response (up to 26 weeks) correlated with APOE genotyping.
Main Results:
- Metrifonate significantly improved cognitive (ADAS-Cog) and global (CIBIC-Plus) functions compared to placebo (p < 0.0001).
- No significant interaction was found between APOE genotype and metrifonate's efficacy on cognitive or global measures (p > 0.25).
- APOE genotype did not independently affect AD progression rates as measured by ADAS-Cog or CIBIC-Plus (p > 0.64).
Conclusions:
- Current evidence does not support a significant interaction between APOE genotype and metrifonate treatment effects in AD patients.
- APOE genotype is unlikely to be a predictor of metrifonate response or a determinant of disease progression in mild to moderate AD.
- Further research may be needed to fully elucidate the role of genetic factors in AD treatment outcomes.